Digitalization is fundamentally changing the life science industry. New technologies and innovations are already enabling pharma companies to improve medicine development and patient care. At the same time, healthcare payers and other customers of pharma companies are demanding more and better data on the medication efficacy and improved patient quality of life. These demands cannot be fulfilled by purely traditional means. It is obvious that the market challenges and requirements can’t be met with the current technologies, products, business models and operations. Therefore the pharma business transformation is inevitable leading to the digitalization of the pharmaceutical products, business models, operations and ultimately – the patient care.
Epista Life Science is a consultancy dedicated to continuously improving regulatory compliance, both for its clients and for the industry. With offices in Denmark and Sweden, and 130+ global clients, Epista’s goal is to turn compliance obstacles into real business opportunities that add value to Life Science companies. Epista pioneers new compliance methodologies, bridge the gap between IT, Quality, and Line-of-Business departments, and benchmark regulatory compliance. The result: Quality organizations that are transparent, predictable and efficient – and that enable the company to reach its business goals.
Pharma industry megatrends leading to digitalization
Beyond the Pill
The New Pharma Reality
The Pharma ecosystem transformation
Clinical development and patient care, Pharma Internet of Things
Product supply, Pharma Industrial Internet (of Things)
Pharma digitalization impact on the value network
Key technologies and platforms
New digital pharma product categories
Precision and personalized medicines
Regulatory and compliance with digitalized products